A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Costs, shortages prompt some hospitals to consider generic-drug manufacturing

by Faith Glazier, Principal, Deloitte Consulting LLP

Four of the nation’s largest hospital systems—Ascension, Intermountain Healthcare, SSM Health, and Trinity Health—are looking into manufacturing some of their own generic drugs, according to recent news reports. At this point, it’s not entirely clear what is driving this decision, but I suspect rising drug costs and/or shortages are likely two big factors.

Based on recent conversations with industry executives,

Read more

Early-stage medtech venture investment is up, driven by digitally-enabled diagnostics. But is the market ready?

by Sonal Shah, Senior Manager, Deloitte Center for Health Solutions, Deloitte Services LP

In my role with the Center for Health Solutions, I spend a fair amount of time researching technology and exploring the impact new medical devices could have on the health care sector. I generally don’t get much first-hand experience with medical devices. That recently changed.

When I told my primary care doctor about some odd sensations I had been feeling in my chest,

Read more

As biosimilars enter the US market, will they be used, and can they reduce spending?

by Erik D. Smith, Ph.D., and Tom Yang, Ph.D., Deloitte Consulting, LLP

Last fall, the Food and Drug Administration (FDA) approved the first biosimilar to treat multiple types of cancer.i While biosimilars have tremendous potential, there also is a good bit of uncertainty around them, particularly in oncology where biologics can have a predominant role in treatment.

February is National Cancer Prevention Month, which gives us a nice opportunity to explore the role biosimilars could play in preventing and treating cancer.

Read more

Targeted cancer therapies are the next frontier of treatment, but room to innovate and improve chemotherapy in the mean time

by Doug Beaudoin, Principal, Deloitte Consulting LLP

It is exciting to learn about new discoveries and breakthroughs in cancer treatment. Certainly the research community has made great strides in both prevention and treatment. The field of immunotherapy is striving to make the patient’s immune system fight back against cancer cells. Researchers have found that combining drugs with different targets can have positive results,

Read more

The 21st century cures act one year later: Big ideas still needed

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

December 13 marked the one-year anniversary of the 21st Century Cures Act. While the law holds tremendous promise for enabling treatments and even cures for disease, multi-sector collaboration – and federal funding – is likely essential if the law is to reach its potential.

The three-year journey that culminated in the passage and enactment of the law was filled with idea generation and questions.

Read more